pharmaphorum20h
Roche trumpets new fenebrutinib data in relapsing MS
The positive readout comes right after Sanofi revealed that its oral BTK drug tolebrutinib failed two phase 3 trials in relapsing MS, although, the company has said it will press ahead with a ...
Applied Clinical Trials Online4h
API-CAT Trial Shows Reduced-Dose Eliquis Matches Full Dose in Preventing Venous Thromboembolism, Lowers Bleeding Risk in Cancer Patients
The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
pharmaphorum20h
10 disruptive technologies that will transform pharma
FDA starts review of Sanofi's MS hope tolebrutinib Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis. R&D ...